Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV gp350-Ferritin Vaccine in EBV-Seronegative Persons
NCT05683834Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Epstein-Barr virus gp350-ferritin vaccine in Epstein-Barr virus infection, infectious mononucleosis (IM), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2023; status: completed.
02
Drugs
Epstein-Barr virus gp350-ferritin vaccine
03
Conditions
Epstein-Barr virus infectioninfectious mononucleosis (IM)
Beyond the preview
Go deeper on NCT05683834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683834.